Summary of Alphatec FY Conference Call (March 11, 2026) Company Overview - **Company**: Alphatec (NasdaqGS: ATEC) - **Industry**: Spine Surgery and Medical Devices Key Points Market Position and Growth Opportunities - Alphatec has made significant progress in the past year, addressing previous concerns regarding capital deployment, financing, and EBITDA, ending the year with strong cash flows and EBITDA [3][4] - The spine surgery market presents substantial growth opportunities, with Alphatec positioned as a smaller player amidst market share shifts among larger competitors [4][12] - The company believes that improving surgical outcomes through better technology will drive market share growth, as high revision rates in spine surgery indicate room for improvement [9][10] Surgeon Adoption and Utilization Metrics - Surgeon adoption rates have been around 20% over the last eight quarters, with a notable 23% in Q4 [21] - New surgeon users tend to drive mid-double-digit volume growth in subsequent years, indicating a long-term utilization improvement [21] - The average selling price (ASP) for cases is expected to grow at a low single-digit rate, reflecting increased complexity in surgeries as surgeons gain experience with Alphatec's products [22][27] Financial Performance and Cash Flow Management - The company achieved a 41% drop-through to reach approximately 12% adjusted EBITDA last year, with a guidance of 32% drop-through for the current year [64][65] - Effective management of inventory and asset deployment is crucial for supporting growth, with a target of 75 cents on the growth dollar basis [65][66] Competitive Landscape and Rep Dynamics - The competitive environment has been influenced by major players like Stryker and J&J making strategic moves, which has lowered the friction for rep transitions and increased the availability of talent [32][41][45] - The selection of new reps reflects the overall market share dynamics, with no significant over-indexing from any particular competitor [39] Technological Innovations - Alphatec is investing in enabling technologies, such as the Valence robot, which aims to enhance surgical precision and efficiency, particularly in complex procedures [50][58] - The Valence robot is positioned at a competitive price point, making it accessible for both large academic settings and community hospitals [58] Conclusion - Alphatec is confident in its growth trajectory, driven by improved surgeon adoption, innovative technologies, and effective cash flow management strategies. The company is well-positioned to capitalize on the evolving landscape of the spine surgery market [8][12][66]

Alphatec Holdings, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance Drivers Achieved 25% annual revenue growth by leveraging a 100% spine-focused strategy in a disrupted market, prioritizing proceduralization over individual products. Expanded the lateral addressable market by converting surgeons from traditional posterior approaches to the proprietary PTP (Prone Transpsoas) technique. Utilized the EOS Edge imaging system as a 'gold standard' entry point to gain access to previously u ...

Core Insights - Alphatec reported strong financial performance for Q4 and full-year 2025, highlighting continued share gains in spine surgery and improved profitability, marking its first full year of positive free cash flow [4][7][12] Financial Performance - Q4 total revenue reached $213 million, a 20% increase year-over-year, with surgical revenue at $190 million and EOS revenue at $23 million [3][10] - Full-year 2025 revenue was $764 million, up 25% year-over-year, driven by a 22% increase in procedural volume and a 3% rise in average revenue per procedure [10][11] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a 16% exit margin [6][9] Growth Drivers - Strategic growth initiatives include leadership in lateral procedures, a controlled rollout of the Valence navigation/robotics platform in 2026, and expanded adoption of EOS/EOS Insight to enhance deformity cases [5][13] - The company signed an exclusive partnership with Theradaptive for a future BMP product, expected to enhance its market position [17] Profitability and Cash Flow - Non-GAAP gross margin for Q4 was 70.5%, up 80 basis points year-over-year, attributed to mix, volume leverage, and improved asset efficiency [8] - The company generated $45 million in cash from operations during 2025, resulting in $3 million of free cash flow, marking a transition to a cash-generating business [12] 2026 Outlook - For 2026, Alphatec projects revenue growth of 17% to approximately $890 million, with surgical revenue expected to be around $805 million [18] - Adjusted EBITDA guidance for 2026 is set at $134 million, implying a margin of about 15%, with expectations for non-GAAP gross margin to approach 71% by year-end [18][19]

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBen Haynor - Managing Director of Medical Technology ResearchPat Miles - CEOTodd Koning - CFOConference Call ParticipantsMatthew Blackman - Research AnalystOperatorGood afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on curr ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsBen Haynor - Managing Director of Medical Technology ResearchPat Miles - CEOTodd Koning - CFOConference Call ParticipantsMatthew Blackman - Research AnalystOperatorGood afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on curr ...

Alphatec (NasdaqGS:ATEC) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker2Good afternoon, everyone, and welcome to the webcast of ATEC's fourth quarter and full year 2025 financial results. We would like to remind everyone that participants on the call will make forward-looking statements. These statements are based on current expectations and are subject to uncertainties that could cause actual results to differ materially. These uncertainties are detailed in documents filed regularly with the S ...

Summary of Alphatec Conference Call Company Overview - **Company**: Alphatec Spine - **Industry**: Medical Supplies and Devices, specifically focused on spinal surgery Key Points and Arguments Growth and Financial Performance - Alphatec aims for long-term differentiated growth, with a strong track record of execution and significant growth opportunities in the spine market [2][3] - The company finished 2025 with $764 million in revenue, reflecting a 25% growth, and expects to reach $890 million in revenue by 2026, representing a 17% growth [4][6] - Adjusted EBITDA for 2025 was projected at $91 million (12% of revenue), with expectations of $130 million (15% margin) by 2026 [4][6] - The company has committed to becoming a $1 billion revenue company by 2027, with $180 million in Adjusted EBITDA [5] Market Position and Strategy - Alphatec is now the third largest U.S. market share holder in the spine market, with less than 10% market share across the top 10 U.S. markets, indicating significant growth potential [5][24] - The company has focused on creating clinical distinction to compel surgeon adoption, achieving over 20% growth in surgeon adoption this year [7][8] - The strategy includes proceduralization, which emphasizes the assembly of goods for spine surgery rather than selling individual parts [3][11] Innovations and Technology - Alphatec has made significant investments in informatics and procedural tools, including the acquisition of EOS, a full-body imaging system, and the development of SafeOp, a neurophysiology tool [19][13] - The company is focused on integrating informatics into surgical workflows to improve decision-making and outcomes, with plans to launch Valence, a navigation and robotic tool, in 2026 [14][15][19] - The informatics play is seen as a key driver of long-term value, with a focus on capturing data to enhance surgical decision-making [24][20] Market Dynamics and Competition - The company views recent disruptions in the spine market, such as spin-offs from larger med tech companies, as potential tailwinds for growth [40][41] - Alphatec believes its commitment to neurophysiology and sophisticated surgical tools provides a competitive advantage over fast-following competitors [44][46] Future Outlook - The company anticipates continued strong growth driven by surgical volume and adoption, with a target of $100 million in EOS revenue by 2027 [32][25] - Seasonality effects are expected to influence revenue patterns, particularly with the growing presence in pediatric deformity [31][35] - Alphatec is focused on maintaining profitability while investing in R&D and sales channels to support growth [50][51] Conclusion - The financial outlook for Alphatec is positive, with a commitment to achieving $890 million in revenue and $130 million in Adjusted EBITDA by 2026, alongside a focus on innovation and market expansion [29][50]

Financial Data and Key Metrics Changes - Total revenue for the third quarter was $197 million, representing a 30% increase year-over-year and a sequential increase of $11 million from the previous quarter [5][14] - Adjusted EBITDA reached $26 million, or 13% of revenue, marking an improvement of 840 basis points compared to the prior year [4][11] - Free cash flow was reported at $5 million, with total cash and available cash amounting to $260 million [12][14] Business Line Data and Key Metrics Changes - Surgical revenue was $177 million, up 31% year-over-year and 5% sequentially, driven by a procedural volume growth of 28% [5][8] - EOS revenue increased to $20 million, a 29% rise compared to the prior year, with strong demand in the U.S. market [8][9] - Same-store sales in the U.S. grew 30% year-over-year, indicating strong performance in established territories [8][9] Market Data and Key Metrics Changes - The company reported a 30% growth in same-store sales, reflecting strong demand in existing markets [8] - The increase in new surgeon users by 26% in the third quarter indicates a growing adoption of the company's products [5][6] Company Strategy and Development Direction - The company remains 100% spine-focused, emphasizing proceduralization and expanding its product offerings in lateral, cervical, and deformity markets [3][19] - The strategic focus includes leveraging technology integration to enhance surgical outcomes and democratize surgical techniques [20][25] - The company is positioned to meet its long-range plan commitments, aiming for $1 billion in revenue by 2027 [17][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable revenue growth and strong profitability improvements [11][17] - The company anticipates raising its full-year revenue guidance by $18 million to $760 million, driven by overperformance in case volume [14][15] - Management highlighted the importance of surgeon adoption and the long-term potential of the spine market, indicating a positive outlook for future growth [18][67] Other Important Information - The company has seen a significant improvement in its operating margin, with a 1,100 basis points expansion year-over-year [10][11] - The trailing 12-month adjusted EBITDA now stands at $81 million, reflecting the company's ability to generate cash flow [11][12] Q&A Session Summary Question: Cash flow expectations for next year - Management expects free cash flow for next year to be around $20 million, aligning with revenue growth and EBITDA drop-through [32][33] Question: Update on long-range plan - An update to the long-range plan is anticipated towards the end of next year as the company progresses through 2026 [34] Question: Competitive landscape and consolidation - The company welcomes market disruption and believes it can capitalize on the current dynamics in the spine market [37][39] Question: Role of Valence in lateral space - Valence is expected to enhance efficiency and democratize surgical techniques, benefiting both experienced and new users [40][44] Question: Health of the spine market and competitive dynamics - The spine market remains healthy, with the company taking share from multiple competitors, reflecting decisions made 18 to 24 months ago [48][50] Question: Balancing growth and profitability - The company aims to balance growth and profitability by investing in innovation while leveraging existing infrastructure [52][54] Question: Timing for deformity portfolio contributions - The company is in the early stages of influencing the deformity market, with several products in the design phase and a focus on expanding EOS availability [73][75]

Financial Data and Key Metrics Changes - The company reported sustained revenue growth, with a guidance of approximately 21% top-line growth for the year [10][12] - Q2 cash usage was at the high end of the guidance range of $0 to $5 million, with expectations of slightly positive free cash flow for the year [5][9] - Adjusted EBITDA profitability is ahead of expectations, contributing to confidence in achieving free cash flow profitability by 2025 [6][26] Business Line Data and Key Metrics Changes - The company added 21% new surgeons in Q2, maintaining a consistent new surgeon metric around 20% over the past eight quarters [15] - Existing territories grew by 29% in Q2, indicating strong surgeon interest and demand [18] Market Data and Key Metrics Changes - The company anticipates a step down in market performance from Q2 to Q3, followed by a rebound from Q3 to Q4 [10][11] - The two-year stack growth rate for Q1 was about $31 million, while Q2 was approximately $34 million, with expectations of $33 million each quarter in the second half [11][12] Company Strategy and Development Direction - The company aims to focus on unique clinical solutions that drive surgeon interest, with a long-term view of improving spine surgery [15] - The upcoming launch of the Valence robot is expected to address clinical challenges and expand the addressable market in spine surgery [31][33] - The company is committed to investing in sales and R&D to drive sustainable growth opportunities while achieving financial commitments [28][74] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the second half of the year, citing strong surgeon adoption and procedural volume growth as tailwinds [30] - The company is optimistic about the clinical value of its solutions, which is expected to drive adoption and utilization rates [48] Other Important Information - The company has been expanding its international presence, particularly in Australia, New Zealand, and Japan, with plans for growth in these markets [49][50] - The PTP Corpectomy launch is seen as a natural evolution within the PTP ecosystem, aimed at enhancing clinical value and procedural volume [55][58] Q&A Session Summary Question: What investor feedback have you received since Q2 results? - Management noted that investors are focused on the durability of top-line growth and the company's profitability profile [4] Question: What gives you confidence in achieving free cash flow profitability in 2025? - Management highlighted better-than-expected performance in the first half of the year and effective cash flow management [5] Question: How do you see the rest of the year playing out from a cash flow perspective? - Management projected free cash flow generation of $1 million to $5 million in Q3 and high single digits in Q4 [9] Question: Can you discuss your recruitment efforts and market environment? - Management indicated a favorable environment for recruitment, with a focus on adding reps to support new surgeon additions [14][15] Question: What are the key performance metrics for new sales reps? - Management explained that new reps typically ramp up over a two-year period, with significant growth potential by year three [20][21] Question: How do you balance attracting new sales talent while achieving cash flow positivity? - Management outlined a structured investment approach in sets and inventory to support revenue growth while maintaining cash flow [24][26] Question: What are your international plans for 2025 and beyond? - Management confirmed a focus on Australia, New Zealand, and Japan, with plans for profitable growth in these markets [49][50] Question: How does the PTP Corpectomy fit into your broader strategy? - Management described PTP as a platform approach that allows for addressing various pathologies, with corpectomy being a natural addition [55][58]

Financial Data and Key Metrics Changes - The company reported a cash usage of $5 million in Q2, at the high end of the guidance range, and expects to achieve slightly positive free cash flow for the year [4][5] - The guidance for top-line growth has been raised to approximately 21% for the year, with expectations of $130 million in total revenue for 2023, 2024, and 2025 [10][12] Business Line Data and Key Metrics Changes - The company achieved a 21% increase in new surgeon adds in Q2, maintaining a consistent growth rate over the past eight quarters [15] - Existing territories grew by 29% in Q2, indicating strong demand and interest from surgeons [19] Market Data and Key Metrics Changes - The company anticipates a slight step down in market performance from Q2 to Q3, followed by a rebound in Q4 [10] - The two-year stack growth rate for Q1 was approximately $31 million, and for Q2 it was about $34 million, with expectations of $33 million for each quarter in the second half [11][12] Company Strategy and Development Direction - The company is focused on compelling surgeons with unique clinical solutions and aims to expand its market share in the spine sector [15] - The upcoming launch of the Valence robot is expected to address clinical challenges in spine surgery, with a focus on integrating it with existing procedures [33][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving free cash flow profitability in 2025, citing better-than-expected performance in the first half of the year [4][5] - The company is optimistic about strong surgeon adoption rates, which are expected to drive procedural volume growth [31] Other Important Information - The company plans to maintain a narrow and deep international strategy, focusing on profitable markets like Australia, New Zealand, and Japan [55][56] - The PTP Corpectomy launch is seen as a natural evolution within the PTP ecosystem, aimed at enhancing clinical value and procedural volume [61][62] Q&A Session Summary Question: What investor feedback have you received since Q2 results? - Investors are focused on the durability of top-line growth and the company's profitability profile [3] Question: What gives you confidence in achieving free cash flow profitability in 2025? - Confidence stems from better-than-expected cash flow performance in the first half of the year [4] Question: How do you see the rest of the year playing out from a cash flow perspective? - Expectations for Q3 are a free cash flow generation of $1 million to $5 million, with high single digits anticipated in Q4 [9] Question: Can you discuss the overall spine market and recruitment efforts? - The company is benefiting from market disruptions and is onboarding sales representatives to support surgeon interest [14] Question: What are the key performance metrics for new sales reps? - New reps typically ramp up over a two-year period, with significant revenue growth expected by year three [21][22] Question: How do you balance attracting new sales talent while achieving cash flow positivity? - The company has a structured investment approach, spending $0.75 for every dollar of year-over-year growth [27][28] Question: What are your international plans for 2025 and beyond? - The focus remains on Australia, New Zealand, and Japan, with plans for growth and profitability in these markets [55][56] Question: How does the PTP Corpectomy fit into the broader ecosystem? - It is seen as a natural evolution that adds clinical value and supports procedural volume growth [61][62]